


DIVISION OF ACUTE CARE SURGERY

Trauma Alcohol Withdrawal Guidelines

Alcohol Withdrawal:

- For INTUBATED patients, if receiving a propofol or midazolam infusion, **NO ADDITIONAL** therapy required while on these infusions.
- EXCLUDED patients: On essential medications that interact with phenobarbital (e.g. HIV meds), hepatic encephalopathy, on phenobarbital chronically, pregnant



Additional Information

- PO dosing preferred unless acute symptom management required, lack of enteral access, or patient unable to swallow safely. PO:IV conversion is 1:1.
- Breakthrough withdrawal symptoms despite maintenance regimen: phenobarbital 65 mg IV q1h prn to goal RASS 0 to -1.
- Hold dose if RASS ≤ -2 or RR ≤ 12 and notify provider
- Avoid benzodiazepines

Considerations

- Soft max cumulative dose: 20 mg/kg (IBW); max cumulative dose: 30 mg/kg (IBW)
 - Patients with IBW <70 kg may need alterations to taper to ensure they do not exceed dose limit.
- If agitation/delirium persists after a total cumulative phenobarbital dose of 20 mg/kg, consider other diagnoses and give additional phenobarbital doses cautiously. **Consult Addiction Psych.**
- If agitation/delirium persists after a total cumulative phenobarbital dose of 30 mg/kg do not give further phenobarbital.

Alcohol Withdrawal Presentation

Signs and symptoms of alcohol withdrawal

Nausea/vomiting Anxiety/agitation

Tremor Visual, tactile, or auditory disturbances

Paroxysmal sweats Clouded sensorium

Tachycardia (> 100 BPM) and hypertension Seizures

 The above symptoms of withdrawal may present within 6-48 hrs after cessation of alcohol and may progress to DTs if untreated.

• Active Delirium Tremens

- DTs consists of alcohol withdrawal symptoms AND acute delirium
- 5% of patients will develop DTs. This typically presents 48-72 hArs after the last drink but has been reported up to 96 hrs later.
- o Typically presents 48-72 hrs after the last drink, but has been reported up to 96 hrs later
- Symptoms of DTs include tachycardia, hypertension, fevers, increased respiratory rate/respiratory alkalosis, visual/auditory hallucinations, and marked agitation. These symptoms may last up to 5 days. The untreated mortality rate may be up to 15%, largely due to the risk of aspiration. As a result, the need for a secure airway should be discussed in patients experiencing DTs

References:

- Tidwell WP, Thomas TL, Pouliot JD, et. al. Treatment of alcohol withdrawal syndrome: phenobarbital vs CIWA-AR protocol. *Am J Crit Care* 2018;27(6):454-460.
- Nisavic MD, Nejad SH, Isenberg BM, et al. Use of phenobarbital in alcohol withdrawal management- A retrospective comparison study of phenobarbital and benzodiazepines for acute alcohol withdrawal management in general medical patients. *Psychosomatics*. 2019;60(5):458-467.
- Oks M, cleven KL, Healy L, et al. The safety and utility of phenobarbital use for the treatment of severe alcohol withdrawal syndrome in the medical intensive care unit. *J Int Care Med*. June 2018, doi: 10.1177/0885066618783947.
- Ammar MA, Ammar AA, Rosen J, Kassab HS, Becher RD. Phenobarbital Monotherapy for the Management of Alcohol Withdrawal Syndrome in Surgical-Trauma Patients. *Annals of Pharmacotherapy*. 2021;55(3):294-302. doi:10.1177/1060028020949137.